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Abstract Islet amyloid polypeptide (lAPP), 'amylin', is the 
component peptide of islet amyloid formed in Type 2 diabetes. 
IAPP is expressed in islet /]-cells and is derived from a larger 
precursor, proIAPP, by proteolysis. An in vitro translation/ 
translocation system was used to separately examine processing 
of human proIAPP by the/I-cell endopeptidases PC2, PC3 or 
furin. ProIAPP was converted to mature IAPP by PC2 but there 
was little conversion by furin or PC3. These data are consistent 
with processing of proIAPP in/]-cell secretory granules. Abnor- 
mal cellular proteolysis associated with type 2 diabetes could 
contribute to lAPP amyloidosis. 
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I. Introduction 
Islet amyloid polypeptide (IAPP), 'amylin', is a component 
peptide of amyloid fibrils deposited in islets of type 2 diabetic 
patients [1,2]. IAPP is colocalised with insulin in the secretory 
granules of islet fl-cells and co-secreted in response to fl-cell 
secretagogues [3,4]. IAPP has been identified in all species ex- 
amined so far [5] and, in common with other secretory peptides, 
is synthesized as a larger precursor molecule. ProIAPP (67 
amino acids in man) is converted to the mature form (37 amino 
acids) by removal of C- and an N-terminal flanking peptides 
[6,7]. Both cleavage sites are conserved inmammals and contain 
pairs of basic amino acids, a common recognition motif for the 
subtilisin-like family of prohormone convertases [8]. 
Several members of the prohormone convertase family have 
been described including PC2, PC3 (also known as PC1), 
PACE4, furin, PC4, PC5 and PC5/6B [9]. PC2 and PC3 are 
expressed inneuroendocrine cells where they are involved in the 
processing of prohormones. PACE4 and furin are expressed in 
a wide range of cell types where they are thought o cleave 
propolypeptides within the constitutive s cretory pathway. PC4 
is expressed in the testis. The expression of PC5 is widespread, 
but its differential splice product PC5/6B is expressed mainly 
in the intestine [9]. 
The subtilisin-like proteases are synthesized as zymogens 
which undergo maturation during their transit through the 
secretory apparatus. PC3 is synthesized as an 88 kDa propol- 
ypeptide which undergoes rapid autocatalytic maturation 
under optimal conditions of neutral pH and low calcium, com- 
patible with the milieu within the endoplasmic reticulum [10]. 
PC2 is synthesized asa 75 kDa propolypeptide which is cleaved 
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to a 68 kDa mature nzyme by a mechanism which occurs at 
pH 5.5 and millimolar calcium, and which is also thought to be 
autocatalytic [11]. This maturation event is likely to occur 
within the later stages of the secretory pathway. Furin is synthe- 
sized as a 90 kDa polypeptide which is cleaved to the 80 kDa 
mature enzyme, an integral membrane protein located within 
the trans Golgi network [12]. PC2, PC3 and furin are calcium- 
dependent proteases which are optimally active at acidic (PC2, 
PC3) or neutral pH (furin). 
The endoprotease(s) responsible for the processing of 
proIAPP is unknown. The fact that IAPP is co-localized with 
insulin in fl-cell granules, and human proinsulin isprocessed by 
the combined action of PC2 and PC3 [13] suggests that these 
enzymes might be involved in proIAPP processing. Alterna- 
tively, proIAPP may be processed in a separate compartment, 
possibly by furin. 
The aim of the present study was to determine whether these 
enzymes were involved in the processing of proIAPP to IAPP. 
An in vitro transcription translation system derived from Xen- 
opus eggs was used [14]. 
2. Materials and methods 
The human IAPP cDNA was obtained from Dr. J.S. Verbeek (Uni- 
versity of Utrecht) [15], the human furin cDNA from Dr. G. Matthews 
(University of Birmingham), and the human PC2 and mouse PC3 
cDNAs were from Dr. D.F. Steiner (University of Chicago). cRNAs 
were prepared using SP6 RNA polymerase in an in vitro transcription 
system [16]. The preparation and use of the Xenopus egg extract trans- 
lation system was as previously described [14]. Products of translation 
were radiolabelled using [3H]leucine since mature lAPP lacks methion- 
ine residues. Translations were terminated after 2 h by addition of 1 pl 
of RNase A (10 mg/ml). Further incubations were optimised to ensure 
activation of the proenzymes and provide optimal conditions for activ- 
ity against proIAPP. For PC3, incubations were allowed to proceed for 
a further 4 h to allow for maturation of proPC3 (pH 7.0, 1 mM 
calcium). The pH was then adjusted to 5.5 and the calcium concentra- 
tion to 10 mM, and the samples incubated overnight. For PC2, the 
samples were immediately adjusted to pH 5.5 and 10 mM calcium and 
the samples incubated overnight. For furin the samples were incubated 
overnight without any additions, i.e. pH 7.0 and 1 mM calcium. Sam- 
ples were then analysed by SDS-PAGE on either 10% polyacrylamide, 
Tris/glycine-buffered (high-Mr; 200-20 kDa) or 13% polyacrylamide, 
Tris/tricine-buffered (low-Mr, 50 2.5 kDa) gels. The use of two gels 
permitted the visualisation fthe high-Mr enzymes and their precursors 
in addition to the low-Mr IAPP molecules. These gels were subsequently 
processed for fluorography. 
3. Results 
3.1. Translation of IAPP and furin mRNA 
Furin mRNA was translated in the Xenopus egg extract and 
the radiolabelled products analysed on high and low molecular 
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N- lAPP  Is let  amylo id  polypeptide C- lAPP  
Human TP IES :  : :HQVEKR 
Monkey . . . . .  : : : . . . . . .  
Cat  . . . . .  : : : N . . . . .  
Dog  - - -K - :  : : - -M- - -  
Rat  - -VG-GTNP- -D- -  
Mouse  - -VR-GSNP-MD- -  
1 37 
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY GKRNRVEVI2KREPLNYLPL  
R . . . . . .  T . . . . . . . . .  D - -  
. . . . . . . . . . . . . . . .  IR  . . . .  L . . . . .  P . . . . . . . . . . .  ST -D I -N  . . . . . . . .  F 
RT- - -L  . . . . .  P . . . . . . . . . . . .  T I - I -N -G . . . . . . .  
R . . . .  L -PV-PP  . . . . . . . . . . . .  VA-DPN- -S -DF-L -  
R . . . .  L -PV-PP  . . . . . . . . . . . . .  AGDPN- -S -DF-KV 
Fig. h Amino acid sequence of proIAPP in 6 mammals. The sequence IAPP 20-29 is conserved inthose species in which the molecule forms amyloid 
fibrils but in rodents there are three proline substitutions. Cleavage sites between the N-(N-IAPP) and C-terminal (C-IAPP) flanking peptides are 
highly conserved as Lys/Arg. A third dibasic site is present in primate C-lAPP. 
weight SDS gels. Two proteins of Mr 100 and 90 kDa were 
observed following a 2 h translation period (Fig. 2, upper 
panel). When the translation reaction was allowed to continue 
overnight, two proteins of 90 kDa and 80 kDa were observed. 
On the low molecular weight gel, a single band at Mr 1 OK was 
present after 2 h translation which increased in intensity with 
overnight incubation (Fig. 2, lower panel). These results repre- 
sent the processing of profurin (100 kDa) to 90 kDa and 80 kDa 
mature forms of the enzyme. The 100 kDa to 90 kDa processing 
event is consistent with N-terminal cleavage of profurin and the 
90 kDa to 80 kDa step could represent either additional N- 
terminal or C-terminal processing. Other proteins of Mr 18K, 
and at 12K were visible but these were present in the absence 
of added mRNA and are likely to be low molecular weight 
proteins synthesized in the extract which are unrelated to the 
enzymes or IAPP. 
Translation of hIAPP mRNA resulted in the appearance of 
a 7.5 kDa proIAPP peptide (Fig. 2, lower panel). Coincubation 
overnight with furin did not alter the intensity of the 7.5 kDa 
band. There was a small amount of processing to the 4 kDa 
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Fig. 2. Co-translation of lAPP and furin cRNAs, lAPP and furin cRNAs were translated in the Xenopus egg extract in the combinations indicated. 
After incubation for 2 h or overnight samples were analysed by Tris/SDS-PAGE and fluorography (upper panel) and Tricine SDS-PAGE and 
fluorography (lower panel). Position of molecular weight markers (with corresponding M r in kDa) are indicated on the left. 
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Fig. 3. Co-translation fIAPP and PC2 cRNAs. IAPP and PC2 cRNAs were translated as indicated in the Xenopus egg extract. After 2 h the extract 
was adjusted to pH 5.5 and 10 mM calcium and incubation was continued overnight. Samples were and analysed by Tris/SDS-PAGE and fluorography 
(upper panel) and Tricine SDS-PAGE and fluorography (lower panel). Position of molecular weight markers (with corresponding Mr in kDa) are 
indicated on the left. 
mature form of iAPP but this was also seen in the absence of 
furin (Fig. 2, lower panel) and was probably due to endogenous 
proteolytic activity within the egg extract. 
3.2. Translation of PC2 and lAPP mRNA 
Translation of PC2 mRNA for 2 h generated a single product 
of 75 kDa (Fig. 3, upper panel), which corresponds to proPC2. 
Following an overnight incubation at pH 5.5 and 10 mM cal- 
cium, the 75 kDa protein was processed to a 68 kDa protein. 
These results are consistent with our previous findings that 
proPC2 undergoes autocatalytic maturation to the 68 kDa ma- 
ture form of the enzyme under these conditions [11]. On the low 
molecular weight gel the cleaved proPC2 propeptide was visible 
as a diffuse band of approximately Mr 9 kDa (Fig. 3, lower 
panel). Coincubation of PC2 and hIAPP overnight resulted in 
a clear processing of proIAPP (7.5 kDa) to mature IAPP (4 
kDa). 
3.3. Translation of PC3 and IAPP mRNA 
As previously described [10], proPC3 (88 kDa) was rapidly 
converted to the 80 kDa mature enzyme in a reaction that was 
optimal at neutral pH and low calcium (Fig. 4, upper panel). 
After 6 h, when almost all of the PC3 was in the mature form, 
conditions were changed to suit the optimal activity of the 
mature enzyme, i.e. pH 5.5 and 10 mM calcium. Under these 
conditions the 80 kDa mature nzyme was stable (Fig. 4, upper 
panel). However, the 8 kDa cleavage fragment of proPC3 (vis- 
ible on the low molecular weight gel as a band at 8 10 kDa) 
underwent further cleavage to a 4 kDa peptide (Fig. 4, lower 
panel). When PC3 and hIAPP mRNA were coincubated over- 
night, the 7.5 kDa proIAPP was unaffected. Although, any 
mature IAPP would have been masked by the presence of the 
4 kDa product of the PC3 propetide there was no reduction of 
the intensity of the proIAPP band in the presence of PC3 (Fig. 
4, lower panel). 
4. Discussion 
The major finding of this study was that proIAPP (7.5 kDa) 
was converted to a mature 4 kDa product by PC2 but not, or 
at least relatively inefficiently, by PC3 or furin. Processing at 
the C-terminal junction therefore involves cleavage by PC2 
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Fig. 4. Co-translation of IAPP and PC3 cRNAs. IAPP and PC3 cRNAs were translated as indicated in the Xenopus egg extract. After 2 h and 
6 h incubation, samples were taken for analysis and the rest of the extract was adjusted to pH 5.5 and 10 mM calcium. Incubation was then continued 
overnight. Samples were analysed by Tris/SDS-PAGE and fluorography (upper panel) and Tricine SDS-PAGE and fluorography. Position of 
molecular weight markers (with corresponding Mr in kDa) are indicated on the left. 
between the R and N residues within the sequence 
TYGKRNAV. At the N-terminal junction, cleavage occurs 
between the R and K residues within the sequence 
VEKRKCNT. The C-terminal cleavage site is similar to other 
PC2 recognition sequences [17], whereas the cleavage between 
basic pairs of residues that occurs at the N-terminal site is not 
a common PC2 recognition site. The finding that PC2 rather 
than furin is involved in proIAPP processing suggests that these 
events occur within a secretory granule compartment where the 
pH and calcium concentration are compatible with the require- 
ments for PC2 enzyme activity. 
Cleavage of human proinsulin requires the combined activity 
of both PC2 and PC3 [10]. It is first cleaved by PC3 at the B 
chain/C peptide junction (KTRR 32) followed by PC2 at the C 
peptide/A chain junction (LQKR65). Proglucagon on the hand 
is processed in the ~ cells solely by PC2 [18]. Interestingly, a 
patient with a primary defect of PC3 activity has been described 
[19]. This patient had a history of insulin resistance and 
hormone disorders associated with elevated plasma concentra- 
tions of intact proinsulin and 64,65 split proinsulin which was 
compatible with a defect in PC3 processing at the B chain/C 
peptide junction. The patient also exhibited efects in the proc- 
essing of the ACTH precursor (POMC); however, there was no 
evidence for aberrant processing of proglucagon [19]. Circulat- 
ing proIAPP was not estimated but the results from our study 
would suggest that processing of IAPP (like that of pro- 
glucagon) would be unaffected in this patient. 
The mechanism of amyloid deposition is not well under- 
stood. NIDDM is associated with increased proportions of 
intact proinsulin and intermediates of proinsulin proteolysis n 
the circulation and with islet amyloid [20,21]. Human insulino- 
mas also have amyloid eposits and associated defects in proin- 
sulin processing [22]. These observations suggest that impaired 
prohormone processing within the secretory pathway of the fl 
cell may be related to the deposition of IAPP in insoluble fibres. 
One possibility is that the maturation or activity of PC2 may 
be affected by abnormalities in control of the ionic environment 
within the secretory pathway. Such abnormalities may also 
affect he intracellular sorting to constitutive or regulated secre- 
tory pathways [23]. It is worth noting that overexpression of
IAPP in COS-1 cells that lack the regulated pathway resulted 
in intracellular amyloid formation [24]. COS-1 cells do not 
express pC2 and so it is unlikely that any proIAPP processing 
occurred in the transfeeted cells. This suggests that proIAPP 
processing is not essential for fibrillogenesis. Extracts of islet 
and insulinoma myloid contain largely mature IAPP but there 
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is evidence of proIAPP in some deposits [25,26]. It is therefore 
possible that proIAPP could have a role in forming an initial 
nidus for progressive fibrillogenesis of IAPP in both diabetes 
and insulinomas. 
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